Aemetis, Inc. (NASDAQ:AMTX) Receives $12.95 Average Price Target from Brokerages

Aemetis, Inc. (NASDAQ:AMTXGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $12.95.

Several equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Aemetis in a report on Monday, December 23rd. StockNews.com raised shares of Aemetis to a “sell” rating in a research note on Wednesday.

View Our Latest Research Report on AMTX

Hedge Funds Weigh In On Aemetis

A number of institutional investors have recently modified their holdings of AMTX. Clear Harbor Asset Management LLC purchased a new stake in Aemetis in the 4th quarter worth approximately $44,000. FMR LLC boosted its holdings in shares of Aemetis by 68.2% during the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock worth $52,000 after purchasing an additional 9,137 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Aemetis in the fourth quarter valued at $87,000. Barclays PLC increased its stake in Aemetis by 274.6% in the third quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after purchasing an additional 34,816 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Aemetis during the third quarter worth about $177,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Price Performance

AMTX opened at $2.04 on Friday. The stock’s 50 day simple moving average is $2.78 and its 200 day simple moving average is $2.85. The stock has a market cap of $101.46 million, a P/E ratio of -0.90 and a beta of 1.44. Aemetis has a 1-year low of $2.01 and a 1-year high of $7.03.

Aemetis (NASDAQ:AMTXGet Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. The firm had revenue of $81.44 million during the quarter, compared to analysts’ expectations of $77.79 million. During the same quarter in the prior year, the business earned ($0.59) EPS. Research analysts expect that Aemetis will post -2.07 EPS for the current fiscal year.

Aemetis Company Profile

(Get Free Report

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.

See Also

Analyst Recommendations for Aemetis (NASDAQ:AMTX)

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.